humanized anti-GD2 antibody

BIOLOGICAL2 trials

Sponsors

St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center

Conditions

NeuroblastomaRecurrent Osteosarcoma

Phase 1

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

CompletedNCT01576692

St. Jude Children's Research HospitalNeuroblastoma

Start: 2012-04-30End: 2018-10-17Updated: 2018-11-15

Phase 2

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active, not recruitingNCT02502786

Memorial Sloan Kettering Cancer CenterRecurrent Osteosarcoma

Start: 2015-07-31End: 2026-07-31Updated: 2025-10-07

Related Papers

High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM).

Journal of Clinical Oncology2019-05-202 citations